Zhang Siwen, Li Yujun, Liu Wenxi, Chu Qi, Wang Shasha, Li Jinyu, Chen Yuwen
School of Medical Device, Shenyang Pharmaceutical University, Shenyang, China.
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Front Med (Lausanne). 2025 Jul 17;12:1630408. doi: 10.3389/fmed.2025.1630408. eCollection 2025.
Artificial intelligence (AI) and medical devices are increasingly integrated, reshaping global diagnostic paradigms. However, the adaptive learning and opaque nature of AI technologies pose significant challenges to traditional regulatory frameworks. In response, regulatory bodies worldwide, including the U.S., EU, China, Japan, and South Korea, have initiated various policies to address the unique risks posed by AI medical devices (AIMD). These efforts aim to balance innovation with patient safety, yet gaps remain in harmonizing standards across regions and ensuring comprehensive oversight. This study provides a comprehensive analysis of the regulatory policies for AIMD from 2015 to 2025 across key global regions. We examine the evolution of these policies, the academic research progress, the limitations of existing regulations, and emerging trends. By reviewing relevant legislation and literature, this paper offers valuable insights for researchers, manufacturers, and regulators to foster the development of robust regulatory frameworks for AIMD.
人工智能(AI)与医疗设备的融合日益紧密,正在重塑全球诊断模式。然而,人工智能技术的自适应学习特性和不透明性给传统监管框架带来了重大挑战。对此,包括美国、欧盟、中国、日本和韩国在内的全球监管机构已出台各项政策,以应对人工智能医疗设备(AIMD)带来的独特风险。这些努力旨在平衡创新与患者安全,但在区域间标准协调和确保全面监管方面仍存在差距。本研究全面分析了2015年至2025年全球主要地区针对AIMD的监管政策。我们考察了这些政策的演变、学术研究进展、现有法规的局限性以及新趋势。通过回顾相关立法和文献,本文为研究人员、制造商和监管机构提供了宝贵见解,以促进建立健全的AIMD监管框架。